The high efficacy of the standard treatment of chronic myeloid leukemia (CML) with imatinib has prompted the need for accurate methods to monitor response at levels below the landmark of complete cytogenetic remission. Quantification of BCR-ABL transcripts has proven to be the most sensitive method available, and has shown prognostic impact with regard to progression-free survival. Until recently, variations in methods used to quantify BCR-ABL made it difficult to compare results between laboratories. An international program is now underway to harmonize the reporting of results according to an international scale (IS). In this review, we consider the background to the IS and the progress that has been made to date, with a particular focus on ongoing harmonization efforts in Europe. We provide recommendations for the propagation of the IS by national or regional laboratory networks.
Introduction
Imatinib mesylate is a rationally designed inhibitor of BCR-ABL, a tyrosine kinase that deregulates intracellular signal transduction and is central to the pathogenesis of chronic myeloid leukemia (CML). 1, 2 Imatinib is the current standard of care in the treatment of CML, and recommendations from the ELN (European LeukemiaNet) and NCCN (National Comprehensive Cancer Network) advocate a dosage of 400 mg daily as a firstline treatment option in patients with CML. 3, 4 Although most CML patients treated with imatinib have an excellent response, monitoring through hematological, cytogenetic and molecular testing is recommended by the ELN and NCCN to promptly identify and optimize treatment for the minority of patients who respond slowly. 3, 4 As most patients with CML treated with imatinib achieve a complete cytogenetic response (CCyR), the measurement of residual disease through sensitive molecular methods (quantification of BCR-ABL transcript levels) has become particularly important for evaluating treatment success in CML. The ELN and NCCN recommendations advocate monitoring for molecular response every 3-6 months, once CCyR has been achieved. [3] [4] [5] This allows the suboptimal responses and primary and acquired resistances to imatinib to be identified early, and treatment to be adjusted accordingly. 5, 6 Second-generation tyrosine kinase inhibitors, such as nilotinib and dasatinib, are rationally designed to target BCR-ABL more effectively. 7 They have also been shown to induce high and early cytogenetic and molecular responses in both imatinibresistant and newly diagnosed CML patients. [8] [9] [10] [11] [12] [13] Quantification of BCR-ABL transcript levels may, therefore, be increasingly important in the future management of CML patients. 14 
Major molecular response
A key marker of molecular response is the so-called major molecular response (MMR), originally classified as a reduction in BCR-ABL transcripts by at least three logs below a standardized baseline value. The level was determined by processing aliquots of the same 30 pretreatment samples in each of the three central laboratories of the International Randomized Study of Interferon versus STI571 (IRIS) trial. 15 Achievement of MMR is associated with improved probability of long-term response and improved progression-free survival (PFS) in patients treated with imatinib. In an initial real-time quantitative PCR (RQ-PCR) analysis of imatinib-treated patients in the IRIS trial, who achieved CCyR at 12 months of treatment, 39% of patients who also achieved MMR had a PFS of 100% at 24 months compared with 95% for patients who did not achieve MMR (P ¼ 0.007). 15 In a later analysis of the entire PCR data set from IRIS, molecular response at 6, 12 and 18 months correlated with long-term outcomes at 72 months in the 476 patients with at least one PCR measurement. MMR rates increased over time, and patients achieving MMR at month 12 of treatment had an event-free survival of 490% and a PFS of 495% at 72 months. Patients achieving MMR and CCyR had better long-term outcomes than those without MMR or CCyR. 16 Druker et al. 17 reported a 5-year follow-up of patients receiving imatinib as part of the IRIS trial. BCR-ABL transcripts were measured in 124 patients who had a CCyR and available blood samples. Cytogenetic and molecular responses had significant associations with PFS; patients who achieved CCyR and MMR after 18 months of treatment had an estimated 100% rate of PFS at 60 months follow-up. Furthermore, patients who achieved CCyR or MMR had a significantly lower risk of disease progression than patients without CCyR (Po0.001).
Cortes et al. 18 investigated the long-term prognostic implications of molecular response in patients with chronic phase CML treated with imatinib at the MD Anderson Cancer Center. They found that achieving MMR, particularly in the first year of therapy, was predictive of durable CCyR; patients who achieved MMR at 12 months after therapy initiation had a significantly longer duration of CCyR than did patients not achieving MMR (P ¼ 0.0004). In this study, MMR was defined as a locally determined BCR-ABL/ABL ratio of o0.05%, which represents the median value of residual disease in patients in CCyR after interferon a therapy. 19 Despite the proven prognostic significance of MMR, wide variations in the methods used to quantify BCR-ABL and lack of widely accepted standards have led to considerable variation in results, making comparability between different laboratories difficult. Standardized reporting of BCR-ABL measurements is needed for optimal clinical management, as well as comparison of measurements from different study groups and pooling of results from different studies.
The international scale for BCR-ABL measurement
In view of the clinical importance of minimal residual disease assessment, efforts have been made to harmonize worldwide BCR-ABL quantification. Harmonization of the detection of minimal residual disease has previously been successfully undertaken in other disease areas, such as acute leukemia. 20 Harmonizing certain pre-analytical and analytical steps can improve the comparability of results even when there are inter-laboratory differences in methods. In CML, the use of standard reference samples has shown the feasibility of harmonization in laboratories using different RQ-PCR platforms. 21, 22 Comparability of results can also be improved by use of a standard control plasmid 23 or a standard control gene.
5,14
Freeze-dried cell preparations offer potential as quality control reagents and could enable the development of international standards. 24 Perhaps the most significant step toward harmonization was made by an expert panel at an international consensus meeting in Bethesda, MD, USA, in 2005. 5 They proposed that BCR-ABL measurements should be expressed on an international scale (IS) that is anchored to two standard values: a standardized baseline value (as established in the IRIS trial) taken to be 100% on the IS, and a standardized MMR value taken to be 0.1% on the IS (that is, a 3-log reduction from the standardized baseline) (Figure 1) . A level of 1-2% IS corresponds roughly to the limit at which Phpositive metaphases can be detected by standard cytogenetics, that is, lower levels of disease are consistent with CCyR. Definition of undetectable disease or complete molecular response (that is, the BCR-ABL level is below the level of sensitivity of the assay) is more difficult because of the inevitable variation between samples and also because the clinical interpretation of negative specimens very much depends on the clinical context and previous results. As a general rule, the Bethesda group recommended that the sensitivity should be at least 0.01% IS, equivalent to a 4-log reduction below the standardized baseline, as indicated by the number of control gene transcripts in the same quantity of cDNA used for the BCR-ABL analysis. 5 These proposals were designed to improve comparability of results while allowing individual laboratories to continue with their established equipment and methodologies. The expert panel recommended that international standardization should be achieved by an exchange of reference standards with values established in reference laboratories. These reference standards would assess the reproducibility of each method and draw attention to inappropriate techniques. It was recommended that reference and quality control samples be developed and made widely available for incorporation into standardized protocols. Although the samples used for definition of the IRIS standardized baseline were limited in quantity and were therefore quickly exhausted, the detailed internal quality control data accrued at regular intervals by the laboratory in Adelaide, Australia, provide excellent traceability of the IS to the IRIS scale.
14,25

Derivation and validation of conversion factors
The only currently available mechanism by which laboratories can adopt the IS is to establish a laboratory-specific conversion factor (CF) (Figure 1 ), using a process initiated by the Adelaide laboratory.
14 Once validated, IS values can be derived by multiplication of local results by the CF. Owing to the distortions resulting from the use of different control genes at high levels of disease, CFs are only valid for levels of disease o10% IS.
For a test laboratory to establish a CF, a series of samples (typically 20-30 samples) are exchanged with a reference laboratory that span at least 3 logs of detectable disease, but do not exceed an IS value of roughly 10%. These samples are then analyzed by both the reference and test laboratories over a period of time to take into account common intra-laboratory variables, for example, different operators and different batches of reagents. Results for the two laboratories are then compared, ideally resulting in two parallel regression lines when plotted on a log scale. The CFs for the test labs are then derived by a straightforward mathematical transformation that results in superposition of the two lines. CFs are then validated by a second exchange of patient samples. It was concluded from experience with this method that the IS can indeed deliver accurate comparison of MMR rates between measurements from different laboratories. 14 
Standardization in Europe
Structure
Following on from the method of CF calculation, a European collaborative harmonization study involving 57 laboratories is currently underway. This is being undertaken under the auspices of the European Treatment and Outcome Study (EUTOS) for CML project, a Europe-wide collaboration to improve standardized evaluation and monitoring, and provide quality-controlled outcomes for CML. The aim is that selected laboratories that have established a validated CF can then exchange samples with other local centers in the manner described above, and thereby propagate a traceable CF to these laboratories. This process is ongoing with the initial establishment of the Mannheim laboratory (AH, MCM and co-workers) as an international reference laboratory by alignment of the results obtained here with those obtained at Adelaide, followed by the development of additional regional or national reference laboratories. Below, we describe our progress toward this goal.
SPOTLIGHT
Derivation of preliminary CFs: methodology
A two-step process is being used to arrive at laboratory-specific CFs to convert measurements of BCR-ABL from each participating laboratory ('local laboratory') to the IS. First, preliminary CFs are calculated using standard samples prepared at the reference laboratory in Mannheim. Second, the Adelaide method 14 is employed to refine the preliminary CF calculations. For the first step, 12 dilution samples are prepared by the reference laboratory for each local laboratory; these dilution samples consist of triplicate dilutions of b3a2 BCR-ABL-positive white blood cells (WBC) from peripheral blood of two untreated chronic phase CML patients (batch 1 and batch 2) in WBC from healthy donors (buffy coats from local blood bank). Samples contain 10 million WBC in batch 1 (n ¼ 40) and 20 million WBC in batch 2 (n ¼ 17), and are designed to approximate up to 10%, 1%, 0.1% and 0.01% BCR-ABL. Dilutions are stabilized using 1 ml Trizol and frozen at À20 1C before being shipped to the local laboratories on dry ice. For validation of CFs, the participating local laboratories are requested to prepare 25-30 CML patient samples consisting of 10-20 million WBC in 1 ml Trizol, covering a range of BCR-ABL levels between 0.01 and 10%. The reference laboratory performs analyses in accordance with the FDA (Food and Drug Administration)-approved guidelines for method comparison using patient samples, after obtaining informed consent and approval of the institutional review board. 26 In addition, the sample sets are analyzed over several RQ-PCR runs to mimic conditions in the original laboratories, including variations arising from different tests, reagent batches and operators. 14 The reference laboratory BCR-ABL quantification is carried out using LightCycler-based methodology (Roche Diagnostics, Mannheim, Germany) and FRET (fluorescence resonance energy transfer) based on two hybridization probes per reaction, using 2 ml cDNA for each PCR run for BCR-ABL, and ABL or GUSB as housekeeping genes as described by Emig et al. 27 and Mü ller et al. 21 Locally established protocols are used for cDNA synthesis, RQ-PCR, housekeeping gene analysis and evaluation methodology in the local laboratories (Table 1) . Duplicate results are sent to the reference laboratory for calculation of CFs.
Log BCR-ABL values for the same sample set (that is, analyzed in both the reference laboratory and local laboratory) are compared between reference and local laboratories by linear regression. Linearity and sensitivity of the respective results are determined for each local laboratory. The results are judged to be linear if R 2 40.98, and non-linear if R 2 o0.98 (Figure 2) . A non-linear fit implies an unsatisfactory amplification efficiency of the respective PCR technique within the meaningful diagnostic range. For laboratories with linear results, preliminary CFs are calculated using the curve characteristics (slope, intercept) and the formulas:
Validation of CFs
Once preliminary CFs for each local laboratory are calculated, they can then be validated. CFs are being validated using the method of Branford et al. 14 Local laboratories at which a preliminary CF had been calculated sent 25-30 patient samples 
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(7)
Control genes
Total ABL (Gabert et al. 30 (EAC protocol), n ¼ 36; Emig et al.
25
, n ¼ 5; in-house methods, n ¼ 5) (either RNA or cells stored in Trizol) to the reference laboratory, where they were then subjected to RQ-PCR analysis. Aliquots of the samples have already been analyzed by the local laboratory using their established procedures, but the local results are not disclosed until analysis at the reference laboratory is complete.
(80)
The preliminary CFs are then used to compare the patient sample results from the reference laboratory (each result multiplied by the Mannheim CF, 0.878) and local laboratories (each result multiplied by their respective preliminary CF). The concordance is recorded by establishing ratios of each local laboratory result with the reference laboratory result. In addition, Bland-Altman bias plots 28, 29 are used to determine the bias between the local laboratory and the reference laboratory. The Bland-Altman method is also used for recalculating CFs. Therefore, the BCR-ABL values from the reference laboratory are first multiplied by 0.878 to convert them to the IS. Log 10 transformation is then performed on both reference and (unmodified) local laboratory data, and the difference between the two sets of data are plotted against the mean of the two results to produce a bias plot. The CF for the local laboratory is calculated as the antilog of the estimated mean bias between the two laboratories.
14 Acceptable concordance between the results of two labs is defined as achievement of two out of the three landmarks, as follows: (i) X50% of the patient samples within a twofold range, that is, the ratio of reference result to local result was between 0.5 and 2.0; (ii) X75% of the patient samples within a threefold range, that is, the ratio of reference result to local result is between 0.33 and 3.0; (iii) X90% of the patient samples within a fivefold range, that is, the ratio of reference result to local result is between 0.2 and 5.0. 14 
Derivation of CFs: initial results
Of 57 local laboratories, 51 produced linear results from their initial sample analyses; results from the other six were nonlinear (Figure 2 ). Preliminary CFs have been calculated for these 51 laboratories (median 0.872, range 0.103-104.7). Applying these CFs to the mean local results of each dilution has led to a clear approximation of the reference results (dilution samples from batch 1: mean coefficient of variation 1.18 versus 0.29 (before versus after conversion); batch 2: mean coefficient of variation 0.63 versus 0.15 (before versus after conversion)) (Figures 3a and b) . To validate these preliminary CFs, the local laboratories have sent frozen patient samples (median n ¼ 28, range 16-74) for a work up in the reference laboratory. A median of 88% of the patient samples (range 28-100) are evaluable. The remainder were not included, for one of the following reasons: (i) BCR-ABL not detectable in either one or both laboratories; (ii) achievable sensitivity within the sample measured by housekeeping gene transcripts (total ABL) below the critical value of 1000 per 2 ml cDNA; (iii) samples contained BCR-ABL transcripts other than b3a2 and/or b2a2 (for example, e1a2, b2a3); and (iv) the mean of the absolute BCR-ABL values from a duplicate measurement was below two transcripts per 2 ml cDNA.
When individual results are multiplied by their respective preliminary CFs, 52% are within a twofold range (0.5-2.0) of reference laboratory results, 76% are within a threefold range (0.33-3.0) and 94% are within a fivefold range (0.2-5.0). Acceptable concordanceFas defined aboveFhas been achieved by 30 of 48 (63%) laboratories, whereas only six of them (13%) reached the group 1 performance characteristics according to Branford et al. 14 (mean difference between ± 1.2-fold and the 95% limits of agreement within ±fivefold).
Refinement of results
As CFs derived from dilution samples cannot always align patient sample results correctly, new CFs have been calculated for 48 local laboratories, using the Bland-Altman bias plot, as described previously.
14 These CFs have produced significantly higher concordance between individual BCR-ABL levels from local laboratories and those from the reference laboratory: 72% are within a twofold range (0.5-2.0), Po0.0001; 90% are within a threefold range (0.33-3.0), Po0.0001; and 96% are within a fivefold range (0.2-5.0), Po0.0001 (Figures 4a-c) . Although 43 of 48 (90%) laboratories meet the criteria for acceptable concordance, there were five which have failed (twofold o50%; threefold o75%; fivefold o90%). These encouraging results are currently undergoing validation by a further exchange of samples.
Recommendations
On the basis of the experience in developing this methodology, we propose recommendations for the successful expansion and longevity of the European network. housekeeping genes, etc., should be accompanied by a thorough internal comparison of the old versus the new method in at least 50 patient samples and a check for differences by applying the Bland-Altman bias plot. In the event of internal evaluations highlighting differences in results (41.2-fold), the laboratory in question should seek reassessment of their CF by a 'higher' laboratory (for example, with another national or international reference laboratory). Second, to identify gradual changes in local CFs over time (even without obvious changes in methodology), a repetition of the 'patient sample' step should be performed on a 2-yearly basis. These recommendations are likely to change with the future availability of internationally established reference materials, which should facilitate greater and more straightforward access to the IS. Further recommendations for national standardization efforts are listed in Table 2 .
Perspectives and future directions
To conclude, BCR-ABL mRNA levels are important predictors of response and relapse in the treatment of CML with imatinib. Monitoring of BCR-ABL levels will also be an important clinical tool for predicting response with new-generation tyrosine kinase inhibitors. Through the EUTOS for CML project, harmonization of molecular monitoring across Europe is taking shape. Currently, out of the 58 laboratories (57 local laboratories and the Mannheim laboratory) covered in this study, 26 are considered to be 'national' reference laboratories in 24 European countries, each with a CF calculated using the method described here (Table 3) . These national reference laboratories are equipped to validate further laboratories within their respective countries, hence propagating validated CFs and the ability of local laboratories to express their BCR-ABL levels on the IS across Europe. In addition to these national laboratories, there are currently 24 local 'non-reference' laboratories able to compare their results in this way (Table 3 ). The EUTOS for CML vision is to expand harmonization even further, to B200 European laboratories, creating a European network of laboratories producing harmonized molecular monitoring results that are linked to the IS. 
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